Publication:

Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice

Date

Date

Date
2024
Journal Article
Published version
cris.lastimport.scopus2025-06-27T03:30:41Z
cris.lastimport.wos2025-07-30T01:31:57Z
dc.contributor.institutionUniversity of Zurich
dc.date.accessioned2024-09-16T13:44:24Z
dc.date.available2024-09-16T13:44:24Z
dc.date.issued2024-09-07
dc.description.abstract

Reward processing dysfunctions e.g., anhedonia, apathy, are common in stress-related neuropsychiatric disorders including depression and schizophrenia, and there are currently no established therapies. One potential therapeutic approach is restoration of reward anticipation during appetitive behavior, deficits in which co-occur with attenuated nucleus accumbens (NAc) activity, possibly due to NAc inhibition of mesolimbic dopamine (DA) signaling. Targeting NAc regulation of ventral tegmental area (VTA) DA neuron responsiveness to reward cues could involve either the direct or indirect-via ventral pallidium (VP)-pathways. One candidate is the orphan G protein-coupled receptor GPR52, expressed by DA receptor 2 NAc neurons that project to VP. In mouse brain-slice preparations, GPR52 inverse agonist (GPR52-IA) attenuated evoked inhibitory postsynaptic currents at NAc-VP neurons, which could disinhibit VTA DA neurons. A mouse model in which chronic social stress leads to reduced reward learning and effortful motivation was applied to investigate GPR52-IA behavioral effects. Control and chronically stressed mice underwent a discriminative learning test of tone-appetitive behavior-sucrose reinforcement: stress reduced appetitive responding and discriminative learning, and these anticipatory behaviors were dose-dependently reinstated by GPR52-IA. The same mice then underwent an effortful motivation test of operant behavior-tone-sucrose reinforcement: stress reduced effortful motivation and GPR52-IA dose-dependently restored it. In a new cohort, GRAB$_{DA}$-sensor fibre photometry was used to measure NAc DA activity during the motivation test: in stressed mice, reduced motivation co-occurred with attenuated NAc DA activity specifically to the tone that signaled reinforcement of effortful behavior, and GPR52-IA ameliorated both deficits. These findings: (1) Demonstrate preclinical efficacy of GPR52 inverse agonism for stress-related deficits in reward anticipation during appetitive behavior. (2) Suggest that GPR52-dependent disinhibition of the NAc-VP-VTA-NAc circuit, leading to increased phasic NAc DA signaling of earned incentive stimuli, could account for these clinically relevant effects.

dc.identifier.doi10.1038/s41398-024-03081-w
dc.identifier.issn2158-3188
dc.identifier.scopus2-s2.0-85203271616
dc.identifier.urihttps://www.zora.uzh.ch/handle/20.500.14742/221193
dc.identifier.wos001306595900001
dc.language.isoeng
dc.subject.ddc610 Medicine & health
dc.title

Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice

dc.typearticle
dcterms.accessRightsinfo:eu-repo/semantics/openAccess
dcterms.bibliographicCitation.journaltitleTranslational Psychiatry
dcterms.bibliographicCitation.number1
dcterms.bibliographicCitation.originalpublishernameNature Publishing Group
dcterms.bibliographicCitation.pagestart363
dcterms.bibliographicCitation.pmid39242529
dcterms.bibliographicCitation.volume14
dspace.entity.typePublicationen
uzh.contributor.affiliationPsychiatrische Universitätsklinik Zürich, University of Zurich
uzh.contributor.affiliationPsychiatrische Universitätsklinik Zürich
uzh.contributor.affiliationPsychiatrische Universitätsklinik Zürich
uzh.contributor.affiliationBoehringer Ingelheim Pharma GmbH & Co. KG
uzh.contributor.affiliationBoehringer Ingelheim Pharma GmbH & Co. KG
uzh.contributor.affiliationBoehringer Ingelheim Pharma GmbH & Co. KG
uzh.contributor.affiliationBoehringer Ingelheim Pharma GmbH & Co. KG
uzh.contributor.affiliationBoehringer Ingelheim Pharma GmbH & Co. KG
uzh.contributor.affiliationPsychiatrische Universitätsklinik Zürich, University of Zurich
uzh.contributor.authorZhang, Chenfeng
uzh.contributor.authorKúkeľová, Diana
uzh.contributor.authorSigrist, Hannes
uzh.contributor.authorHengerer, Bastian
uzh.contributor.authorKratzer, Ramona F
uzh.contributor.authorMracek, Philipp
uzh.contributor.authorOmrani, Azar
uzh.contributor.authorvon Heimendahl, Moritz
uzh.contributor.authorPryce, Christopher R
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceNo
uzh.contributor.correspondenceYes
uzh.document.availabilitypublished_version
uzh.eprint.datestamp2024-09-16 13:44:24
uzh.eprint.lastmod2025-07-30 01:37:30
uzh.eprint.statusChange2024-09-16 13:44:24
uzh.harvester.ethYes
uzh.harvester.nbNo
uzh.identifier.doi10.5167/uzh-262129
uzh.jdb.eprintsId25183
uzh.oastatus.unpaywallgold
uzh.oastatus.zoraGold
uzh.publication.citationZhang, Chenfeng; Kúkeľová, Diana; Sigrist, Hannes; Hengerer, Bastian; Kratzer, Ramona F; Mracek, Philipp; Omrani, Azar; von Heimendahl, Moritz; Pryce, Christopher R (2024). Orphan receptor-GPR52 inverse agonist efficacy in ameliorating chronic stress-related deficits in reward motivation and phasic accumbal dopamine activity in mice. Translational Psychiatry, 14(1):363.
uzh.publication.freeAccessAtdoi
uzh.publication.originalworkoriginal
uzh.publication.publishedStatusfinal
uzh.scopus.impact0
uzh.scopus.subjectsPsychiatry and Mental Health
uzh.scopus.subjectsCellular and Molecular Neuroscience
uzh.scopus.subjectsBiological Psychiatry
uzh.workflow.doajuzh.workflow.doaj.true
uzh.workflow.eprintid262129
uzh.workflow.fulltextStatuspublic
uzh.workflow.revisions34
uzh.workflow.rightsCheckkeininfo
uzh.workflow.sourcePubMed:PMID:39242529
uzh.workflow.statusarchive
uzh.wos.impact0
Files

Original bundle

Name:
s41398_024_03081_w.pdf
Size:
2.79 MB
Format:
Adobe Portable Document Format
Publication available in collections: